| 摘要 |
This invention provides a method of therapeutical conversion from a long-acting release (LAR) formulation of octreotide, e.g. Sandostatin(R) LAR(R), to pegvisomant (Somavert(R)) for the acromegalic patients through a therapeutically overlapping transition period to a final dose range of pegvisomant established.
|
